BioCryst Pharmaceuticals, Inc. Share Price & Technical Analysis
BCRX · $8.29 (-0.96%)
Healthcare / Drug Manufacturers - Specialty & Generic
$8.29
-0.96%
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to …
Price chart
Seasonality
May has 4 positive and 1 negative years (last 5 years shown)
-10% return in May, 28% avg return in past 3 year May month.
15% return in 2026, -3% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -15% | 33% | 10% | -3% | -10% | – | – | – | – | – | – | – | 15% |
| 25 | 4% | 12% | -13% | 19% | 21% | -17% | -10% | 2% | -10% | -3% | 0% | 10% | 16% |
| 24 | -10% | 4% | -11% | -18% | 55% | -7% | 18% | 19% | -12% | 5% | -6% | 1% | 38% |
| 23 | -9% | -16% | -8% | -8% | 9% | -16% | 6% | -7% | -1% | -21% | 7% | 2% | -62% |
| 22 | 11% | 7% | -2% | -43% | 1% | 14% | 4% | 28% | -9% | 4% | 10% | -14% | 10% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Weak
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$2.19B
P/E ratio
—
52W high
$11.31
52W low
$6.00
Volume
41,65,156
Beta
0.57
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is BioCryst Pharmaceuticals, Inc. share price today?
- BioCryst Pharmaceuticals, Inc. (BCRX) last traded around $8.29 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does BCRX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for BCRX. Download the app for real-time alerts.
- How can I analyze BioCryst Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.